Drug Profile
Research programme: polycefin therapeutics - Arrogene
Alternative Names: AG-103Latest Information Update: 06 Apr 2023
Price :
$50
*
At a glance
- Originator Arrogene
- Class Antisense oligonucleotides; Biopolymers
- Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor inhibitors; Laminin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Brain cancer; Breast cancer; Lung cancer
Most Recent Events
- 06 Apr 2023 Polycefin therapeutics is still in preclinical trials for Brain cancer, Lung cancer and Triple negative breast cancer in USA (Arrogene pipeline, March 2023)
- 25 Apr 2016 Preclinical trials in Lung cancer in USA (IV) before April 2016 (Arrogene 10-K, April 2016)
- 25 Apr 2016 Arrogene plans to file an IND application with the US FDA for Brain tumours (Arrogene 10-K, April 2016)